Clinical trial

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

NCT06733922

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-27

PhasePHASE4

Study timeline

Study start (actual)2024-11-27Date precision: day

Registry last updated2026-05-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)unresolved

Interventions

ETNATM-ProgMSDEVICE

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

MontrealQuebec, Canada3 CalgaryAlberta, Canada2 HalifaxNova Scotia, Canada2 VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 EdmontonAlberta, Canada1 QuébecQuebec, Canada1 SherbrookeQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06733922 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.